{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:02:24Z","timestamp":1786546944309,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Australian NHMRC Leadership Investigator Grants"},{"name":"Australian NHMRC synergy grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-026-05968-z","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T16:32:25Z","timestamp":1780763545000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of the effect of primaquine dose on efficacy, safety, and tolerability in patients with Plasmodium vivax malaria in Ethiopia: a systematic review and individual patient data meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Tamiru Shibiru","family":"Degaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamala","family":"Thriemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha","family":"Rajasekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tesfay","family":"Abreha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashenafi","family":"Assefa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas M.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Endalamaw","family":"Gadisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asrat","family":"Hailu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimee","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin C. K. W.","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus V. G.","family":"Lacerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Llanos-Cuentas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Abebe","family":"Mekonnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fitsum G.","family":"Tadesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter R. J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"von Seidlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adugna","family":"Woyessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asnakew K.","family":"Yeshiwondim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Yilma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ric N.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudissa Assefa","family":"Bayissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Commons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"5968_CR1","unstructured":"Ethiopia Service Provision Assessment 2021\u201322 Final Report. 2023. http:\/\/www.ephi.gov.et. Accessed 26 Dec 2025."},{"key":"5968_CR2","unstructured":"National Malaria Guidelines, fifth edition, August 2022. https:\/\/ict.moh.gov.et\/elibrary\/public_documents. Accessed 26 Dec 2025."},{"key":"5968_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/1756-3305-4-30","author":"A Alemu","year":"2011","unstructured":"Alemu A, Abebe G, Tsegaye W, Golassa L. Climatic variables and malaria transmission dynamics in Jimma town, South West Ethiopia. Parasit Vectors. 2011. https:\/\/doi.org\/10.1186\/1756-3305-4-30.","journal-title":"Parasit Vectors"},{"key":"5968_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-023-04656-6","author":"H Teka","year":"2023","unstructured":"Teka H, Golassa L, Medhin G, Balkew M, Sisay C, Gadisa E, et al. Trend analysis of malaria in urban settings in Ethiopia from 2014 to 2019. Malar J. 2023. https:\/\/doi.org\/10.1186\/s12936-023-04656-6.","journal-title":"Malar J"},{"key":"5968_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-280","author":"GK John","year":"2012","unstructured":"John GK, Douglas NM, Von Seidlein L, Nosten F, Baird JK, White NJ, et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J. 2012. https:\/\/doi.org\/10.1186\/1475-2875-11-280.","journal-title":"Malar J"},{"issue":"10195","key":"5968_CR6","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S0140-6736(19)31096-7","volume":"394","author":"KE Battle","year":"2019","unstructured":"Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, et al. Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000\u201317: a spatial and temporal modelling study. Lancet. 2019;394(10195):332\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(19)31096-7.","journal-title":"Lancet"},{"key":"5968_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-018-2538-4","author":"A Assefa","year":"2018","unstructured":"Assefa A, Ali A, Deressa W, Tsegaye W, Abebe G, Sime H, et al. Glucose-6-phosphate dehydrogenase (G6PD) deficiency in Ethiopia: absence of common African and Mediterranean allelic variants in a nationwide study. Malar J. 2018. https:\/\/doi.org\/10.1186\/s12936-018-2538-4.","journal-title":"Malar J"},{"key":"5968_CR8","unstructured":"Perine PL, Tesfa Michael M. A preliminary survey for glucose-6-phosphate dehydrogenase deficiency and haemoglobin S in Ethiopia. Ethiop Med J. 1974;4."},{"issue":"1","key":"5968_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-438","volume":"13","author":"A Tsegaye","year":"2014","unstructured":"Tsegaye A, Golassa L, Mamo H, Erko B. Glucose-6-phosphate dehydrogenase deficiency among malaria suspects attending Gambella hospital, southwest Ethiopia. Malar J. 2014;13(1):438. https:\/\/doi.org\/10.1186\/1475-2875-13-438.","journal-title":"Malar J"},{"key":"5968_CR10","unstructured":"Malaria - Ethiopia. https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2024-DON542. Accessed 23 Sep 2025."},{"issue":"2","key":"5968_CR11","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S1473-3099(23)00430-9","volume":"24","author":"RJ Commons","year":"2024","unstructured":"Commons RJ, Rajasekhar M, Edler P, Abreha T, Awab GR, Baird JK, et al. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis. Lancet Infect Dis. 2024;24(2):172\u201383. https:\/\/doi.org\/10.1016\/S1473-3099(23)00430-9.","journal-title":"Lancet Infect Dis"},{"key":"5968_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-018-0487-3","author":"HS Taffese","year":"2018","unstructured":"Taffese HS, Hemming-Schroeder E, Koepfli C, Tesfaye G, Lee MC, Kazura J, et al. Malaria epidemiology and interventions in Ethiopia from 2001 to 2016. Infect Dis Poverty. 2018. https:\/\/doi.org\/10.1186\/s40249-018-0487-3.","journal-title":"Infect Dis Poverty"},{"key":"5968_CR13","unstructured":"Ethiopia Malaria Elimination Strategic plan: 2021\u20132025. https:\/\/ict.moh.gov.et\/elibrary\/public_documents. Accessed 27 Sep 2025."},{"key":"5968_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-021-03906-9","author":"M Tarekegn","year":"2021","unstructured":"Tarekegn M, Tekie H, Dugassa S, Wolde-Hawariat Y. Malaria prevalence and associated risk factors in Dembiya district, North-western Ethiopia. Malar J. 2021. https:\/\/doi.org\/10.1186\/s12936-021-03906-9.","journal-title":"Malar J"},{"key":"5968_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-023-04635-x","author":"A Abebe","year":"2023","unstructured":"Abebe A, Menard D, Dugassa S, Assefa A, Juliano JJ, Lo E, et al. Significant number of Plasmodium vivax mono-infections by PCR misidentified as mixed infections (P. vivax\/P. falciparum) by microscopy and rapid diagnostic tests: malaria diagnostic challenges in Ethiopia. Malar J. 2023. https:\/\/doi.org\/10.1186\/s12936-023-04635-x.","journal-title":"Malar J"},{"issue":"10202","key":"5968_CR16","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0140-6736(19)31285-1","volume":"394","author":"WRJ Taylor","year":"2019","unstructured":"Taylor WRJ, Thriemer K, von Seidlein L, Yuentrakul P, Assawariyathipat T, Assefa A, et al. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet. 2019;394(10202):929\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(19)31285-1.","journal-title":"Lancet"},{"issue":"3","key":"5968_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","volume":"13","author":"Z Munn","year":"2015","unstructured":"Munn Z, MClinSc SM, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc. 2015;13(3):147\u201353. https:\/\/doi.org\/10.1097\/XEB.0000000000000054.","journal-title":"Int J Evid Based Healthc"},{"key":"5968_CR18","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook#how-to-cite. Accessed 7 Feb 2026."},{"key":"5968_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002299","author":"T Abreha","year":"2017","unstructured":"Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, et al. Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: a randomized controlled trial. PLoS Med. 2017. https:\/\/doi.org\/10.1371\/journal.pmed.1002299.","journal-title":"PLoS Med"},{"issue":"3","key":"5968_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/nejmoa1802537","volume":"380","author":"A Llanos-Cuentas","year":"2019","unstructured":"Llanos-Cuentas A, Lacerda MVG, Hien TT, V\u00e9lez ID, Namaik-larp C, Chu CS, et al. Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019;380(3):229\u201341. https:\/\/doi.org\/10.1056\/nejmoa1802537.","journal-title":"N Engl J Med"},{"issue":"2","key":"5968_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.actatropica.2009.10.001","volume":"113","author":"AK Yeshiwondim","year":"2010","unstructured":"Yeshiwondim AK, Tekle AH, Dengela DO, Yohannes AM, Teklehaimanot A. Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia. Acta Trop. 2010;113(2):105\u201313. https:\/\/doi.org\/10.1016\/j.actatropica.2009.10.001.","journal-title":"Acta Trop"},{"key":"5968_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-023-04562-x","author":"DA Mekonnen","year":"2023","unstructured":"Mekonnen DA, Abadura GS, Behaksra SW, Taffese HS, Bayissa GA, Bulto MG, et al. Treatment of uncomplicated Plasmodium vivax with chloroquine plus radical cure with primaquine without G6PDd testing is safe in Arba Minch, Ethiopia: assessment of clinical and parasitological response. Malar J. 2023. https:\/\/doi.org\/10.1186\/s12936-023-04562-x.","journal-title":"Malar J"},{"issue":"1","key":"5968_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12936-025-05510-7\/TABLES\/2","volume":"24","author":"VSH Ruwanpura","year":"2025","unstructured":"Ruwanpura VSH, Phongchantha V, Price RN, Grietens KP, Thriemer K, Lynch CA. Strengthening country ownership of national antimalarial policymaking: insights from Laos, Pakistan and the Solomon Islands. Malar J. 2025;24(1):1\u201314. https:\/\/doi.org\/10.1186\/S12936-025-05510-7\/TABLES\/2.","journal-title":"Malar J"},{"issue":"1","key":"5968_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-019-13412-X","volume":"10","author":"AR Taylor","year":"2019","unstructured":"Taylor AR, Watson JA, Chu CS, Puaprasert K, Duanguppama J, Day NPJ, et al. Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. Nat Commun. 2019;10(1):5595. https:\/\/doi.org\/10.1038\/S41467-019-13412-X.","journal-title":"Nat Commun"},{"issue":"8","key":"5968_CR25","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1093\/cid\/ciy735","volume":"68","author":"CS Chu","year":"2019","unstructured":"Chu CS, Phyo AP, Turner C, Win HH, Poe NP, Yotyingaphiram W, et al. Chloroquine versus dihydroartemisinin-piperaquine with standard high-dose primaquine given either for 7 days or 14 days in Plasmodium vivax malaria. Clin Infect Dis. 2019;68(8):1311\u20139. https:\/\/doi.org\/10.1093\/cid\/ciy735.","journal-title":"Clin Infect Dis"},{"issue":"10417","key":"5968_CR26","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/S0140-6736(23)01553-2","volume":"402","author":"K Thriemer","year":"2023","unstructured":"Thriemer K, Degaga TS, Christian M, Alam MS, Rajasekhar M, Ley B, et al. Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P. falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial. Lancet. 2023;402(10417):2101\u201310. https:\/\/doi.org\/10.1016\/S0140-6736(23)01553-2.","journal-title":"Lancet"},{"key":"5968_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00729-7","author":"TS Degaga","year":"2026","unstructured":"Degaga TS, Pasaribu AP, Tripura R, Ghanchi N, Rajasekhar M, Adhikari B, et al. Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial. Lancet Infect Dis. 2026. https:\/\/doi.org\/10.1016\/S1473-3099(25)00729-7.","journal-title":"Lancet Infect Dis"},{"key":"5968_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-019-1386-6","author":"RJ Commons","year":"2019","unstructured":"Commons RJ, Simpson JA, Thriemer K, Chu CS, Douglas NM, Abreha T, et al. The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. BMC Med. 2019. https:\/\/doi.org\/10.1186\/s12916-019-1386-6.","journal-title":"BMC Med"},{"issue":"2","key":"5968_CR29","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S1473-3099(23)00431-0","volume":"24","author":"M Rajasekhar","year":"2024","unstructured":"Rajasekhar M, Simpson JA, Ley B, Edler P, Chu CS, Abreha T, et al. Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis. Lancet Infect Dis. 2024;24(2):184\u201395. https:\/\/doi.org\/10.1016\/S1473-3099(23)00431-0.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"5968_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/S12936-025-05425-3","volume":"24","author":"SA Cassidy-Seyoum","year":"2025","unstructured":"Cassidy-Seyoum SA, Mwaura M, Chheng K, Kejela M, Korra KG, Wodaj T, et al. Co-design of a routine clinical review to improve the safety of high dose radical cure treatment for Plasmodium vivax malaria: findings from Cambodia and Ethiopia. Malar J. 2025;24(1):171. https:\/\/doi.org\/10.1186\/S12936-025-05425-3.","journal-title":"Malar J"},{"key":"5968_CR31","doi-asserted-by":"publisher","unstructured":"High daily dose Short COurse PrimaquinE after G6PD testing for the radical cure of Plasmodium vivax malaria in Indonesia and Papua New Guinea: the SCOPE implementation study protocol. BMC Infect Dis. 2025 Jul 16;25(1):922. https:\/\/doi.org\/10.1186\/S12879-025-11109-9.","DOI":"10.1186\/S12879-025-11109-9"},{"key":"5968_CR32","unstructured":"Update List of Authorized Clinical Trials In Ethiopia \u2013 EFDA. https:\/\/www.efda.gov.et\/publication\/update-list-of-authorized-clinical-trials-in-ethiopia\/. Accessed 23 Sep 2025."},{"issue":"3","key":"5968_CR33","doi-asserted-by":"publisher","first-page":"e467","DOI":"10.1016\/S2214-109X(23)00542-9","volume":"12","author":"M Brito","year":"2024","unstructured":"Brito M, Rufatto R, Murta F, Sampaio V, Balieiro P, Ba\u00eda-Silva D, et al. Operational feasibility of Plasmodium vivax radical cure with tafenoquine or primaquine following point-of-care, quantitative glucose-6-phosphate dehydrogenase testing in the Brazilian Amazon: a real-life retrospective analysis. Lancet Glob Health. 2024;12(3):e467\u201377. https:\/\/doi.org\/10.1016\/S2214-109X(23)00542-9.","journal-title":"Lancet Glob Health"},{"key":"5968_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-023-02022-3","author":"K Thriemer","year":"2023","unstructured":"Thriemer K, Commons RJ, Rajasekhar M, Degaga TS, Chand K, Chau NH, et al. The heterogeneity of symptom reporting across study sites: a secondary analysis of a randomised placebo-controlled multicentre antimalarial trial. BMC Med Res Methodol. 2023. https:\/\/doi.org\/10.1186\/s12874-023-02022-3.","journal-title":"BMC Med Res Methodol"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-026-05968-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05968-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05968-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:05:06Z","timestamp":1786543506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12936-026-05968-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5968"],"URL":"https:\/\/doi.org\/10.1186\/s12936-026-05968-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8963274\/v1","asserted-by":"object"}]},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All data included in this analysis were obtained in compliance with national ethical regulations and approvals. According to the Oxford Human Research Ethics Committee, no additional ethics approval was required for this analysis.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors of the studies have granted permission for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"293"}}